Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor David Preiss

Associate Professor David Preiss

David Preiss

PhD FRCPath MRCP


Associate Professor

  • Honorary Consultant in Metabolic Medicine

MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit

David Preiss studied medicine at the University of Pretoria, South Africa and, after junior doctor training posts in medicine and biochemistry in Scotland, qualified as a consultant in Chemical Pathology and Metabolic Medicine in Glasgow in 2012. He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University of Glasgow’s Bellahouston Medal for this research. He was recipient of a Rising Star Fellowship from the European Foundation for the Study of Diabetes in 2013, and was also awarded the Royal College of Pathology’s Research Medal for Clinical Biochemistry in 2010. He was appointed as a Senior Clinical Research Fellow at CTSU in September 2015 and as Associate Professor in 2018. 

His major interest is the prevention of cardiovascular disease with particular focus on lipid modification and diabetes. His current research combines clinical trials, epidemiological studies and meta-analyses of major studies. Current projects include:

  • LENS: a randomised trial investigating the effect of the cholesterol and triglyceride-lowering drug, fenofibrate, on the progression of diabetic eye disease in 1,150 participants with diabetes and observable retinopathy or maculopathy
  • ORION-4a randomised trial investigating the effect of the LDL cholesterol-lowering drug, inclisiran, on major cardiovascular events in 15,000 participants with cardiovascular disease
  • EMPA-KIDNEY: a randomised trial investigating the effect of the SGLT2 inhibitor, empagliflozin, on worsening of kidney disease or cardiovascular death in 6,500 participants with chronic kidney disease
  • ASCEND PLUS: a planned randomised trial investigating the effect of the GLP1 receptor agonist, oral semaglutide, on major cardiovascular events in 20,000 participants with type 2 diabetes
  • Cholesterol Treatment Trialists' Collaboration: analyses of adverse event data from randomised controlled trials of statin therapy

Key publications

Recent publications

More publications